Optimer Pharmaceuticals Announces Presentations of Data From the Fidaxomicin Phase 3 Trials at ECCMID

SAN DIEGO, April 6 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data from the fidaxomicin Phase 3 clinical studies will be presented at the 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria.  

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin vs. vancomycin"

Poster presenter:  Derrick Crook, M.D.

Saturday, April 10, 2010 3:30pm–4:30pm Central European Summer Time (6:30am-7:30am PST)

Presentation number: LB2401

"Three simple ESCMID severity criteria predict poor cure rate and slower resolution of diarrhea in Clostridium difficile infection"

Poster presenter:  Mark A. Miller, M.D.

Saturday, April 10, 2010 3:30pm-4:30pm Central European Summer Time (6:30am-7:30am PST)

Presentation number: LB2394

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection. Optimer has reported positive top-line results from two Phase 3 trials of fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Optimer has also successfully completed two Phase 3 trials with Pruvel. Additional information can be found at http://www.optimerpharma.com.

SOURCE Optimer Pharmaceuticals, Inc.